NASDAQ : LBRX

LB Pharmaceuticals Inc — Company profile

Healthcare · Biotechnology · United States

Last price 39.7 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 1.28B

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.

Details

NameLB Pharmaceuticals Inc
SectorHealthcare
IndustryBiotechnology
Employees49
Founded2015
Ipo Date2025-09-11
CeoHeather Turner
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price15.00
IsinUS50180M1080
Cusip50180M108
Cik1691082
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Heather D. Turner Esq., J.D.Chief Executive Officer and Director
Gad SofferChief Operating and Business Officer
Joseph M. Miller CPAChief Financial Officer
Minako Pazdera J.D., Ph.D.General Counsel
Lindsay BeaupreSenior Vice President of People and Culture
Dr. Richard A. Silva Ph.D.Senior Vice President of Technical Operations
Dr. James Rawls Pharm.D.Senior Vice President of Regulatory Affairs
Ellen RoseSenior Vice President of Corporate Affairs
Kaya Pai Panandiker KamleshChief Commercial Officer
Christopher ZergebelSenior Vice President of Clinical Operations

Contact

AddressOne Pennsylvania Plaza, Suite 1025, New York, New York 10119, United States
Phone212 605 0300
Websitehttps://lbpharma.us